XML 41 R20.htm IDEA: XBRL DOCUMENT

Revenue (Tables)

3 Months Ended

Mar. 31, 2026

Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss

Revenue has been recognized in the unaudited condensed consolidated interim statements of profit or loss with the following amounts:


	Three Months Ended March 31,
(EUR’000)	2026		2025
Revenue
Commercial products		240,853		96,028
Services and clinical supply		5,110		3,524
Licenses		638		1,402
Total revenue		246,601		100,954
Specified per geographical area
United States (1)		209,076		73,633
Europe (2)		36,318		21,328
Rest of world (1)		1,207		5,993
Total revenue		246,601		100,954

(1)

Beginning with the year ended December 31, 2025, revenue related to the United States has been disclosed separately. Comparatives for the United States and Rest of world have been restated for comparative purposes.

For the three months ended March 31, 2026 and 2025, Denmark, the country of domicile, contributed €4.5 million and €2.4 million, respectively, of revenue.

Schedule of Revenue From Sale of Commercial Products

Revenue from sale of commercial products was as follows:


	Three Months Ended March 31,
(EUR’000)	2026		2025
Revenue from commercial products
YORVIPATH®		196,896		44,688
SKYTROFA®		43,957		51,340
Total revenue from commercial products		240,853		96,028